Prominent Scientists at the Washington University School of Medicine in St. Louis are working on a nasal COVID-19 vaccine that apparently proves effective in mice susceptible to the coronavirus. The recent study reveals that the early-stage, experimental vaccine can be administered with just one dose to the nasal region leading to strong immune reactions in the mice. Next on the radar are the study of non-human primates and thereafter, hopefully, humans.
With the recent publication of this study in Cell, the scientists report that the study deviates from other vaccines via the method of administration. The team uncovered that delivery through the nasal was actually more effective in triggering the immune response sufficiently robust to resist, and fight the pathogen. Even more interestingly, this investigational vaccine created more powerful preventative elements seemingly protecting the body from the pathogen penetrating the respiratory tracts notoriously susceptible to the virus.
An adenovirus, it was weakened, ensuring that this novel vaccine didn’t trigger a common cold while also modified to include two mutations to the spike protein necessary to combat novel coronaviru...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).